Clinical trials: Metastatic Malignant Neoplasm to Brain
Advanced Solid Tumors, HER2-positive Breast Cancer
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.
- Trial name
- NCT04487236
- Testing
- ZN-A-1041 50mg BID, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Suzhou Zanrong Pharma Limited
Melanoma, Renal Cell Carcinoma
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
The purpose of this study is to collect prospective data for use as a comparator for future subsequent studies attempting to increase the efficacy or reduce the toxicity of gamma knife radiosurgery.
- Conditions
- Melanoma, Renal Cell Carcinoma, Sarcoma, Breast Cancer
- Trial name
- NCT02005614
- Testing
- Gamma Knife Radiosurgery
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Metastatic Cancer
Adjuvant Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Adjuvant radiation therapy may kill any remaining tumor cells following surgery or radiosurgery for brain metastases.
- Trial name
- NCT00002899
- Testing
- adjuvant therapy, radiation therapy, stereotactic radiosurgery
- Where
- 33 sites in Belgium, Finland and 11 more
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain Neoplasms, Adult, Malignant
Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis
SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses.
- Trial name
- SRS (NCT02645487)
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
TNBC, Brain Metastasis
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases
- Trial name
- NCT06210438
- Testing
- SHR-A1921 + Bevacizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Metastatic Melanoma, Brain Metastases
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
This is a study to test the efficacy of using standard immune therapy for melanoma prior to stereotactic radiosurgery (ipilimumab induction), as compared to stereotactic radiosurgery followed by immune therapy.
- Trial name
- NCT02097732
- Testing
- Ipilimumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Irradiation; Adverse Effect
Minocycline Therapy for Management of Adverse Radiation Effects
Stereotactic radiosurgery (SRS) is a well-established treatment for patients with metastatic brain tumors. Although SRS has a very high tumor growth control these interventions are associated with adverse radiation effects (ARE)…
- Trial name
- NCT02201563
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Pittsburgh
Brain Metastases, Lung Cancer Metastatic
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer…
- Conditions
- Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic
- Trial name
- NCT03638765
- Testing
- DCVax-Direct
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwest Biotherapeutics
Non-Small Cell Lung Cancer, Leptomeningeal Metastases
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or…
- Conditions
- Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases
- Trial name
- NCT02616393
- Testing
- Tesevatinib
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Kadmon Corporation, LLC
Brain Metastases, Adult, Breast Cancer
BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast…
- Trial name
- BEAT-Breast (NCT06611306)
- Testing
- DE-iPTV
- Where
- 2 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Brain Cancer
Safety Study of Afatinib for Brain Cancer
The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer.
- Trial name
- NCT02423525
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Santosh Kesari
Non-small Cell Lung Cancer, Brain Metastases
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Subject population：Patients with brain metastases from EGFR mutation-positive non-small cell lung cancer who have not received systemic treatment. Experimental design: Single-center, single-arm phase II clinical trial.
- Trial name
- NCT04978753
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Li-kun Chen
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases…
- Conditions
- Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
- Trial name
- TUXEDO-3 (NCT05865990)
- Testing
- Patritumab deruxtecan
- Where
- 8 sites in Austria, Spain
- Volunteers
- 63 people
- Sponsor
- MedSIR
NSCLC, EGFR Gene Mutation
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
This study involves patients with EGFR-mutated NSCLC and asymptomatic brain metastases. This is an open-label, randomized study, comparing the continuation of Osimertinib treatment alone to Osimertinib treatment combined with…
- Conditions
- NSCLC, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05033691
- Testing
- Stereotactic surgery
- Where
- Israel
- Volunteers
- 162 people
- Sponsor
- Hadassah Medical Organization
Brain Metastases
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.
- Trial name
- NCT02747303
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- University of Chicago
Tumors Metastatic to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery
This pilot clinical trial studies how well voxel based diffusion tensor imaging in predicting response in patients with brain metastases undergoing whole-brain radiation therapy or stereotactic radiosurgery.
- Trial name
- NCT02277561
- Testing
- diffusion tensor imaging, whole-brain radiation therapy, stereotactic radiosurgery
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Leptomeningeal Carcinomatosis, Leptomeningeal Metastases
ANG1005 in Leptomeningeal Disease From Breast Cancer
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated…
- Conditions
- Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases, HER2-negative Breast Cancer
- Trial name
- ANGLeD (NCT03613181)
- Testing
- ANG1005, Physician's Best Choice
- Volunteers
- 150 people
- Sponsor
- Angiochem Inc
Brain Metastases
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
This trial is a pilot, Phase 2, sequential two-cohort study designed to test two de-escalated whole brain radiation therapy (WBRT) dose levels and assess their ability to maintain acceptable in-brain distant control.
- Trial name
- NCT03189381
- Testing
- Cohort A, Cohort B
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Brain Metastases, Brain Metastases, Adult
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of…
- Conditions
- Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer
- Trial name
- NCT05559853
- Testing
- CEST-MRF
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who…
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00039572
- Testing
- boronophenylalanine-fructose complex
- Where
- 2 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.